Heartflow, Inc.

Heartflow, Inc.

HTFLNYSE / NASDAQHealthcareSmall cap

$46.69+$2.06 (+4.6%)

Last close · Data as of Nov 20, 2026

Market cap
$2.5B
P/E
-21.3x
EV / EBITDA
-26.4x
Revenue
$176.0M
Net margin
-66.3%
ROCE
-20.2%

+68.7% over the last year

Heartflow, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-16.0%
3M
-0.2%
6M
+70.5%
1Y
+68.7%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change +$2.06 (+4.6%) from $45 to $47 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HTFL, bought on each weekday since 2025.

News & filings

What Heartflow filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 117 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 30.9% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide.

Read moreShow less

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in Mountain View, California.

Sector
Healthcare
Shares outstanding
85.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.5B
P/E
-21.3x
P/B
8.3x
EV / EBITDA
-26.4x
EV / Sales
14.0x
P/S
14.1x
52-week high
$60.53
52-week low
$20.49

Profitability

Operating margin
-36.4%
Net margin
-66.3%
EBITDA margin
-52.9%
ROE
-38.8%
ROCE
-20.2%
ROIC
-28.9%
ROA
-32.5%
Asset turnover
0.49

Growth

Revenue
$176.0M
Revenue growth, 1Y
39.9%
Net profit growth, 1Y
21.1%
Free cash flow
-$59.0M

Solvency

Current ratio
5.20
Debt / Equity
0.07
Debt / Assets
0.06
CFO / Net profit
0.46
Cash / Market cap
1.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$176.0M
Cost of revenue$40.8M
Gross profit$135.2M
Operating expenses$199.3M
Research and development$64.9M
Selling, general and administrative$134.3M
Operating income-$64.1M
Interest and other-$52.8M
Pretax income-$116.9M
Tax and other-$80.0k
Net income-$116.8M

Revenue and net profit

Revenue grew 39.9% in FY2025; net profit is the dashed line.

Heartflow, Inc. revenue and net profit by fiscal year
Heartflow, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$87.2M-$95.7M
FY2024$125.8M-$96.4M
FY2025$176.0M-$116.8M

Cash flows

FY2025: -$54.0M from operations, -$59.0M free after investment (dashed).

Heartflow, Inc. operating and free cash flow by fiscal year
Heartflow, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023-$76.4M-$82.5M
FY2024-$69.0M-$73.4M
FY2025-$54.0M-$59.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$176.0M+39.9%1Y
EBITDA
-$93.1M
Net profit
-$116.8M
Cash from operations
-$54.0M
Free cash flow
-$59.0M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$176.0M-$93.1M-$116.8M-$59.0M-38.8%+39.9%+21.1%

Monthly returns

Month-by-month returns of HTFL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$359.4M
Liabilities$58.8M
Equity$300.6M
Paid-in capital$1.4B
Retained earnings-$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HTFL highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Heartflow, Inc. (this company)14.0x

Not shown (no positive earnings and no EV / Sales): Definium Therapeutics, Inc., Vera Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Heartflow, Inc.HTFLthis company$2.5B-21.3x8.3x-38.8%-26.4x
Definium Therapeutics, Inc.DFTX$2.7B-14.6x8.1x-55.3%-13.8x
Alumis Inc.ALMS$2.6B-10.7x8.6x-80.8%-5.7x
Tarsus Pharmaceuticals, Inc.TARS$2.6B-39.1x7.6x-19.3%-45.8x
Guardian Pharmacy Services, Inc.GRDN$2.6B52.5x12.6x23.9%26.5x
IDEAYA Biosciences, Inc.IDYA$2.6B-22.6x2.5x-11.1%-16.0x
Vera Therapeutics, Inc.VERA$2.4B-8.0x4.0x-49.6%-7.3x
Celldex Therapeutics, Inc.CLDX$2.3B-9.1x4.5x-49.1%-8.2x
Axogen, Inc.AXGN$2.3B—17.5x-12.2%4471.2x
Peer median—-10.7x7.8x-34.2%-7.7x

Year-to-date ROI

HTFL since 1 January, against earlier years.

Historical volatility

HTFL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Heartflow, Inc. operating margin by fiscal year
Heartflow, Inc. operating margin by fiscal year
DateOperating margin
FY2023-83.6%
FY2024-48.7%
FY2025-36.4%
LineFY2025
Cost of revenueCost Of Revenue$40.8M
Gross profitGross Profit$135.2M
Operating expensesOperating Expense$199.3M
Research and developmentResearch And Development$64.9M
Selling, general and administrativeSelling General And Administration$134.3M
Total expensesTotal Expenses$240.1M
Pretax incomePretax Income-$116.9M

Learn while you research

Academy chapters picked for Heartflow, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing40% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →